Xylem to release Q3FY26 results on October 27, 2026

0 min read | Published on 30 Sept 2026, 01:53 AM |Updated on 30 Sept 2026, 01:53 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Xylem Inc. releases Q3FY26 results on October 27, 2026
Investor conference call scheduled for 9:00 am ET same day
Company reported $9 billion revenue in 2025
Telephone replay available until November 10, 2026

*this image is generated using AI for illustrative purposes only.

Xylem Inc. (NYSE: XYL) will release its third quarter 2026 financial results at 6:55 am (ET) on October 27, 2026. The global water solutions company follows this with an investor conference call later that morning.

Earnings call details

Senior management will host a conference call with investors at 9:00 am (ET) on the same day. Participants can access the live briefing by dialing +1 (866) 777-2509 for US callers or +1 (412) 317-5413 for international participants. Alternatively, listeners may join via the company's investor events webpage.

Replay availability

A replay of the earnings briefing will be accessible through two channels:

Online: Available on the Xylem Investors Events page.
Telephone: Available at +1 (855) 669-9658 (US) or +1 (412) 317-0088 (INTL) using Access Code #9823594.

The telephone replay remains active from 1:00 pm (ET) on October 27, 2026, until 11:59 pm (ET) on November 10, 2026.

Company profile

Xylem is a Fortune 500 company focused on water security. The firm employs 22,000 people and reported revenue of $9 billion in 2025. Its operations center on optimizing water and resource management through innovation.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will Xylem's Q3 2026 performance compare to its 2025 baseline of $9 billion in revenue?

What specific guidance regarding 2027 capital expenditures might management provide during the October 27 conference call?

How are emerging water security regulations expected to impact Xylem's future growth trajectory and market share?

Xylem affirms Q3 EPS guidance of $1.42-$1.47 vs $1.46 estimate

0 min read | Published on 18 Aug 2026, 08:34 PM |Updated on 18 Aug 2026, 08:34 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Xylem Inc reaffirms Q3 adjusted EPS guidance of $1.42-$1.47 and sales of $2.300 billion. Both figures miss analyst estimates of $1.46 and $2.316 billion respectively, indicating a conservative outlook compared to market consensus.

*this image is generated using AI for illustrative purposes only.

Xylem Inc (NYSE: XYL) has reaffirmed its financial guidance for the third quarter, maintaining its adjusted earnings per share (EPS) outlook at $1.42 to $1.47. The company also confirmed its sales guidance for the period at $2.300 billion.

Both metrics fall short of market expectations. The affirmed EPS range sits below the analyst consensus estimate of $1.46, while the sales outlook is lower than the estimated $2.316 billion. The company did not provide updated figures for revenue growth rates or margin expansions in this update.

Guidance Details

The reaffirmed guidance indicates no change from previous internal projections despite the variance with external estimates.

Metric:	Xylem Guidance:	Analyst Estimate:
Adj EPS (Q3):	$1.42 - $1.47	$1.46
Sales (Q3):	$2.300 billion	$2.316 billion

What the Numbers Show

The divergence between Xylem’s internal guidance and analyst estimates suggests a cautious stance on near-term performance. With the midpoint of the EPS guidance ($1.445) falling below the consensus estimate ($1.46), and sales guidance trailing by $16 million, the data points to potential headwinds or conservative execution assumptions relative to market sentiment.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the divergence between Xylem's conservative guidance and higher analyst estimates impact short-term stock volatility and institutional investor sentiment?

What specific operational headwinds or macroeconomic factors could be driving Xylem's cautious stance on Q3 sales and EPS compared to market expectations?

Will Xylem management provide updated commentary on revenue growth rates and margin expansion trends in upcoming investor calls to address the lack of detail in this update?